Trial · NCT03946527
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
NCT03946527, Phase 2, Active not recruiting, Antonio Fojo
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA). Trials, record NCT03946527. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03946527
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
- NCT number
- NCT03946527
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- Antonio Fojo
- Conditions
- Paraganglioma, Pheochromocytoma
- Interventions
- Lanreotide
- First posted
- 2019-05-10
- Last updated
- 2026-03-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of tumor growth | minimum of 32 weeks, up to 48 weeks | Efficacy will be assessed by measuring the tumor growth rate while a patient is enrolled on study and comparing the growth rates on lanreotide to the pre-enrollment growth rates. Tumor growth measured by a CT or MRI scan in pre-treatment, and minimum of three scans (prior to every 3rd visit, or every 12 weeks) in post-treatment. |
| Secondary | Overall survival (OS) | Observed for 48 weeks (start of treatment to end of treatment). | The length of time from the start of treatment that subjects with the disease are still alive. |
| Secondary | Overall Response Rate (ORR) | Minimum of 8 weeks, up to 48 weeks. | ORR is defined as the proportion of the subjects in the analysis population who have a complete response (CR) or partial response (PR). Responses are based on assessments per RECIST 1.1. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria. * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have change in short axis to less than 10 mm. * Partial Response (PR): At least a 30% change in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
| Secondary | Progression-free survival | Up to 48 weeks. | PFS is defined as the time from the first day of treatment to the first documented disease progression per RECIST 1.1 criteria and the Kaplan-Meier curve. Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria. |
| Secondary | Magnitude of change in analyte levels | Minimum of 16 weeks, up to 48 weeks. | Biochemical response of greater than 20% change in 24-hour urinary metanephrines, catecholamines and serum chromogranin A levels compared to baseline, sustained for \>12-week-period. Evaluated every two months while enrolled on study, although levels may be obtained as frequently as the investigator desires. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03946527
GET https://conductscience.org/api/trials/v1/NCT03946527/registered